title: Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors.
abstract: Combinational therapies are often required in the management of type 2 diabetes mellitus (T2DM). Among the important candidates, dipeptidyl peptidase-4 inhibitors (DPPIs) and metformin combination (DPPI-MET) have shown promising endeavors. In order to examine the efficacy and safety of such a combination therapy in T2DM patients finding inadequate control with metformin, this systematic review and meta-analysis has been conducted. Literature search was made in multiple electronic databases. Inclusion criteria included; RCTs examining the efficacy and safety of DPPI-MET against placebo-MET or MET-only groups of T2DM patients by observing changes in disease endpoints including HbA1c and FPG, and the length of trial be at least 12 weeks. Mean differences based meta-analyses were performed and heterogeneity assessment was carried out. Nineteen studies were selected and included in the meta-analyses. DPPI-MET significantly improved all disease endpoints and the difference could be noticed up to 2 years in the majority of outcome measures. In comparison with PBO-MET, the DPPI-MET combinational therapy resulted in the percent HbA1c changes from baseline with a mean difference [95% CI] of -0.77 [-0.86, -0.69] in 3-month (P < 0.00001), -0.67 [-0.76, -0.59] in 6-month (P < 0.00001), -0.67 [-0.88, -0.47] in 1-year (P < 0.00001) and -0.36 [-0.53, -0.20] in 2-year trials (P < 0.0003). Reduction in body weight and safety profile in the treated and control groups were not different. A combinational therapy with DPPI and metformin significantly improves diabetes clinical indicators and this effect has been observed for up to 2 years herein. Safety and tolerability of DPPI-MET combination have been found well-manageable with a very similar adverse event profile in both treated and control groups.
authors.affiliation: Department of Clinical Pharmacy, Unaizah College of Pharmacy, Qassim University, P.O. Box 1627, Hail 81441, Saudi Arabia.
authors.forename: Abdulrahman S
authors.initials: AS
authors.lastname: Alanazi
keywords: Combinational therapy; DPPIs; Diabetes mellitus; Dipeptidyl peptidase-4 inhibitors; Metformin